



PRESS RELEASE

Lund April 26, 2011

RAPID DEVELOPMENT IN JAPAN - 10 SYSTEM OF EXINI BONE™ INSTALLED IN THE PERIOD FEB-APRIL

FUJIFILM own the exclusive rights to the Japanese version of EXINI Bone™ and has already installed 10 systems at various clinics throughout Japan. The agreement was signed as late as January 27, 2011.

The customized version of EXINI Bone™, referred to as "Bononavi" in the Japanese market, has been very successful. Extensive testing in several steps has been made on a number of hospitals in Japan. The outcome of the tests has been excellent and is the basis for the three-year agreement signed earlier this year.

- "We are very excited about our partnership with EXINI. The combination of our wide range of pharmaceuticals within nuclear medicine and EXINI's high-tech software is a perfect match," says Morita Toshiya, General Manager Marketing, FUJIFILM RI Pharma Co. Ltd., and continues: "I am very impressed over EXINI's adjustment to our demanding Japanese market. Always on time! "
- Magnus Aurell, CEO EXINI, comments: "The rapid market penetration FUJIFILM have made on such short time and already installed 10 systems around Japan is impressive. The agreement with FUJIFILM is important for many reasons. Partly through their significant role as one of the leaders in the Japanese isotope market and of course the international interest the agreement creates. We also see opportunities for additional sales where EXINI Bone with its unique BSI (Bone Scan Index for prediction of bone metastases in patients with breast or prostate cancer) will be followed by some of our other products.

The agreement with FUJIFILM is three years with a total value of SEK 15 million for installation and license, which makes EXINI's business cash flow positive already in 2011.

For more information, please contact:

Magnus Aurell, CEO

Phone: 046-286 54 25

E-mail: magnus.aurell @ exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make their own interpretation of radiology images and providing diagnostic suggestions. In this way the system is used as a decision support for diagnosing sparkling doctor. EXINI working on products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. Founded in 1999 by Professor Lars Brandt and Eden currently has 12 employees. EXINI is listed on the stock market square and has about 250 shareholders. Principal owner, Bo Håkansson.